Cargando…

Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?

BACKGROUND: Incidence of attention deficit hyperactivity disorder (ADHD) in children and adolescents has been increasing. The disorder results in high societal costs. Policymakers increasingly use health economic evaluations to inform decisions on competing treatments of ADHD. Yet, health economic e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schawo, Saskia, van der Kolk, Annemarie, Bouwmans, Clazien, Annemans, Lieven, Postma, Maarten, Buitelaar, Jan, van Agthoven, Michel, Hakkaart-van Roijen, Leona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544537/ https://www.ncbi.nlm.nih.gov/pubmed/25715975 http://dx.doi.org/10.1007/s40273-015-0259-x

Ejemplares similares

Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands
por: van der Kolk, Annemarie, et al.
Publicado: (2015)

The cost-effectiveness of family/family-based therapy for treatment of externalizing disorders, substance use disorders and delinquency: a systematic review
por: Goorden, Maartje, et al.
Publicado: (2016)

Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate
por: van der Schans, Jurjen, et al.
Publicado: (2015)

Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag)
por: Schapperer, Elisabeth, et al.
Publicado: (2015)

Employment and the associated impact on quality of life in people diagnosed with schizophrenia
por: Bouwmans, Clazien, et al.
Publicado: (2015)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Galactorrhea Probably Related with Switching from Osmotic-release Oral System Methylphenidate (MPH) to Modified-release MPH: An Adolescent Case
por: Ekinci, Ozalp, et al.
Publicado: (2017)

Update of the Dutch manual for costing studies in health care
por: Kanters, Tim A., et al.
Publicado: (2017)

Let’s get back to work: survival analysis on the return-to-work after depression
por: Vemer, Pepijn, et al.
Publicado: (2013)

Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
por: Kooij, J J Sandra, et al.
Publicado: (2013)

Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults
por: Liu, Tao, et al.
Publicado: (2019)

Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)
por: Bouwmans, Clazien, et al.
Publicado: (2013)

Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
por: Buitelaar, Jan K, et al.
Publicado: (2009)

Dose titration of osmotic release oral system methylphenidate in children and adolescents with attention-deficit hyperactivity disorder: a retrospective cohort study
por: Xu, Youran, et al.
Publicado: (2023)

Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea
por: Kim, Bung-Nyun, et al.
Publicado: (2011)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Study on the Complexation and Release Mechanism of Methylphenidate Hydrochloride Ion Exchange Resin Complex
por: Li, Conghui, et al.
Publicado: (2021)

Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder()
por: Mizuno, Kei, et al.
Publicado: (2013)

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
por: Pliszka, Steven R., et al.
Publicado: (2017)

Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed‐Release and Extended‐Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations
por: Incledon, Bev, et al.
Publicado: (2022)

Methylphenidate-associated myopathy
por: Vargas, Ana Beatriz, et al.
Publicado: (2012)

The cardiovascular safety of methylphenidate
por: Jackson, John W
Publicado: (2016)

Editorial: Attention and Methylphenidate
por: Avital, Avi, et al.
Publicado: (2020)

A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Soutullo, César, et al.
Publicado: (2013)

Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release
por: Weiss, Margaret, et al.
Publicado: (2019)

Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?
por: Bukstein, Oscar G, et al.
Publicado: (2009)

An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety
por: Döpfner, Manfred, et al.
Publicado: (2011)

Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder
por: Takon, Inyang
Publicado: (2011)

Surveillance of Diversion and Nonmedical Use of Extended-Release Prescription Amphetamine and Oral Methylphenidate in the United States
por: Sembower, Mark A., et al.
Publicado: (2013)

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial
por: Rezaei, Farzin, et al.
Publicado: (2015)

Reproductive toxicology. Methylphenidate hydrochloride.
Publicado: (1997)

ADHD, Methylphenidate, and Childhood Epilepsy
por: Sharma, Rahul, et al.
Publicado: (2016)

Methylphenidate significantly improves declarative memory functioning of adults with ADHD
por: Verster, Joris C., et al.
Publicado: (2010)

Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder
por: Safavi, Parvin, et al.
Publicado: (2016)

Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
por: Song, Dong-Ho, et al.
Publicado: (2012)

An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder
por: Zheng, Yi, et al.
Publicado: (2015)

The search for relevant outcome measures for cost-utility analysis of systemic family interventions in adolescents with substance use disorder and delinquent behavior: a systematic literature review
por: Schawo, S., et al.
Publicado: (2017)

Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence
por: Rothenberger, Aribert, et al.
Publicado: (2011)

An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
por: Rothenberger, Aribert, et al.
Publicado: (2011)

Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder
por: Lamberti, Marco, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5vgge4h54nn6gd579j4guu3eaf